However, despite these encouraging findings, there remains a gap in understanding whether CXCR4 antagonists can effectively address peripheral blood neutropenia, abnormal BM neutrophil counts, and infection susceptibility specifically in patients harboring CXCR2 LOF variants. This evidence concerns the gene CXCR4 and Decreased total neutrophil count.